small molecule

OZOBAX

BACLOFEN

Loss of exclusivityAugust 2039latest FDA-listed patent expiry
CompanyMETACEL PHARMACEUTICALS LLC

Drug detail

Brand nameOZOBAX
Active ingredientBACLOFEN
Strength5MG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
10610502August 2039use U-2779

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OZOBAX patent cliff — loss of exclusivity August 2039 | CliffBio